Management of medication-overuse headache

References

• Peters GA, Horton BT. Headache with special reference to the excessive use of ergotamine preparations and withdrawal effects. Proc. Staff Meet. Mayo. Clin.26, 153–161 (1951).
   PubMed Web of Science ®Google Scholar
• Horton BT, Peters GA. Clinical manifestations of excessive use of ergotamine preparations and management withdrawal effect-report of 52 cases. Headache3, 214–226 (1963).
   Google Scholar
• Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia8(Suppl. 7), 1–96 (1988).
   Web of Science ®Google Scholar
• International Headache Society. The International Classification of Headache Disorders. Cephalalgia24, 1–160 (2004).
   Web of Science ®Google Scholar
• Silberstein SD, Olesen J, Bousser MG et al. The International Classification of Headache Disorders, (2nd Edition) – revision of criteria for 8.2 Medication-overuse headache. Cephalalgia25, 460–465 (2005).
   PubMed Web of Science ®Google Scholar
• Olesen J, Bousser MG, Diener HC et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia26, 742–746 (2006).
   PubMed Web of Science ®Google Scholar
• Diener HC, Dahlof CG. Headache associated with chronic use of substances. In: The Headaches(2nd Edition). Olesen J, Tfelt-Hansen P, Welch KM (Eds). Lippincott, Williams & Wilkins, Philadelphia, PA, USA 871–878 (1999).
   Google Scholar
• Lance F, Parkes C, Wilkinson M. Does analgesic abuse cause headache de novo? Headache38, 61–62 (1988).
   Google Scholar
• Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular analgesic use? Headache43, 179–190 (2003).
   PubMed Web of Science ®Google Scholar
• Zwart JA, Dyb G, Hagen K et al. Analgesic use – a predictor of chronic pain and medication overuse headache-the Head-HUNT Study. Neurology61, 160–164 (2003).
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Schneeweiss S, Kurth T et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology62(5), 788–790 (2004).
   PubMed Web of Science ®Google Scholar
• Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology59, 1011–1014 (2002).
   PubMed Web of Science ®Google Scholar
• Meskunas CA, Tepper SJ, Rapoport AM, Sheftell FD, Bigal ME. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache46, 766–772 (2006).
   PubMed Web of Science ®Google Scholar
• Paemeleire K, Bahra A, Evers S, Matharu MS, Goadsby PJ. Medication-overuse headache in patients with cluster headache. Neurology67, 109–113 (2006).
   PubMedGoogle Scholar
• Reuter U, Salomone S, Ickstein GW, Waeber C. Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats. Cephalalgia24, 398–407 (2004).
   PubMed Web of Science ®Google Scholar
• Saucier C, Morris SJ, Albert PR. Endogenous serotonin-2A and -2C receptors in Balb/c-3T3 cells revealed in serotonin-free medium-desensitisation and down-regulation by serotonin. Biochem. Pharmacol.56, 1347–1357 (1998).
   PubMed Web of Science ®Google Scholar
• Tohyama Y, Yamane F, Fikre Merid M, Blier P, Diksic M. Effects of serotonin receptor agonists, TFMPP and CGS12066B, on regional serotonin synthesis in the rat brain – an autoradiographic study. J. Neurochem.80, 788–798 (2002).
   PubMed Web of Science ®Google Scholar
• Dobson CF, Tohyama Y, Diksic M, Hamel E. Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain. Cephalalgia24, 2–11 (2004).
   PubMed Web of Science ®Google Scholar
• Srikiatkhachorn A, Anthony M. Platelet serotonin in patients with analgesic-induced headache. Cephalalgia16, 423–426 (1996).
   PubMed Web of Science ®Google Scholar
• Srikiatkhachorn A, Tarasub N, Govitrapong P. Effect of chronic analgesic exposure on the central serotonin system – a possible mechanism of analgesic abuse headache. Headache40, 343–350 (2000).
   PubMed Web of Science ®Google Scholar
• Bendtsen L, Jensen R, Olesen J. Decreased pain detection and tolerance thresholds in chronic tension-type headache. Arch. Neurol.53, 373–376 (1996).
   PubMed Web of Science ®Google Scholar
• De Tommaso M, Libro G, Guido M et al. Heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in chronic tension-type headache. Pain104, 111–119 (2003).
   PubMed Web of Science ®Google Scholar
• Ayzenberg I, Obermann M, Nyhuis P et al. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia26, 1106–1114 (2006).
   PubMed Web of Science ®Google Scholar
• Schmidt-Wilcke T, Leinisch E, Straube A et al. Gray matter decrease in patients with chronic tension type headache. Neurology65, 1483–1486 (2005).
   PubMed Web of Science ®Google Scholar
• Fumal A, Laureys S, Di Clemente L et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain129, 543–550 (2006).
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Woodson PP. Caffeine physical dependence – a review of human and laboratory animal studies. Psychopharmacology94, 437–451 (1988).
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Woodson PP. Reinforcing properties of caffeine-studies in humans and laboratory animals. Pharmacol. Biochem. Behav.29, 419–427 (1988).
   PubMed Web of Science ®Google Scholar
• van Dusseldorp M, Katan MB. Headache caused by caffeine withdrawal among moderate coffee drinkers switched from ordinary to decaffeinated coffee-a 12 week double blind trial. Br. Med. J.300, 1558–1559 (1990).
   PubMed Web of Science ®Google Scholar
• Silverman K, Evans SM, Strain EC, Griffiths RR. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N. Engl. J. Med.327, 1109–1114 (1992).
   PubMed Web of Science ®Google Scholar
• Scher AI, Stewart WF, Lipton RB. Caffeine as a risk factor for chronic daily headache – a population-based study. Neurology63, 2022–2027 (2004).
   PubMed Web of Science ®Google Scholar
• Ziegler DK. Opiate and opioid use in patients with refractory headache. Cephalalgia14, 5–10 (1994).
   PubMed Web of Science ®Google Scholar
• Fisher MA, Glass S. Butorphanol (Stadol) – a study in problems of current drug information and control. Neurology48, 1156–1160 (1997).
   PubMed Web of Science ®Google Scholar
• Saper JR, Jones JM. Ergotamine tartrate dependency – features and possible mechanisms. Clin. Neuropharmacol.9, 244–256 (1986).
   PubMed Web of Science ®Google Scholar
• Fanciullacci M, Alessandri M, Pietrini U, Briccolani-Bandini E, Beatrice S. Long-term ergotamine abuse-effect on adrenergically induced mydriasis. Clin. Pharm. Ther.51, 302–307 (1992).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Cicero AFG, Bertolini A, Leone S, Pasciullo G, Sternieri E. Need for analgesics/drugs of abuse – a comparison between headache patients and addicts by the Leeds Dependence Questionnaire (LDQ). Cephalalgia26, 187–193 (2005).
   Google Scholar
• Fuh J-L, Wang S-J, Lu S-R, Juang K-D. Does medication overuse headache represent a behavior of dependence? Pain119, 49–55 (2005).
   PubMed Web of Science ®Google Scholar
• Castillo J, Munoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache39, 190–196 (1999).
   PubMed Web of Science ®Google Scholar
• Colas R, Munoz P, Temprano R, Gomez C, Pascual J. Chronic daily headache with analgesic overuse – epidemiology and impact on quality of life. Neurology27, 1338–1342 (2004).
   Google Scholar
• Lanteri-Minet M, Auray JP, El Hasnaoui A. Prevalence and description of chronic daily headache in the general population of France. Pain102, 143–149 (2003).
   PubMed Web of Science ®Google Scholar
• Lu SR, Fuh JL, Chen WT, Juang KD, Wang SJ. Chronic daily headache in Taipei, Taiwan-prevalence, follow-up and outcome predictors. Cephalalgia21, 980–986 (2001).
   PubMed Web of Science ®Google Scholar
• Prencipe M, Casini AR, Ferretti C et al. Prevalence of headache in an elderly population-attack frequency, disability, and use of medication. J. Neurol. Neurosurg. Psychiatr.70, 377–381 (2001).
   PubMed Web of Science ®Google Scholar
• Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache38, 497–506 (1998).
   PubMed Web of Science ®Google Scholar
• Wang SJ, Fuh JL, Lu SR et al. Chronic daily headache in Chinese elderly – prevalence, risk factors, and biannual follow-up. Neurology54, 314–319 (2000).
   PubMed Web of Science ®Google Scholar
• Wang SJ, Fuh JL, Lu SR, Juang KD. Chronic daily headache in adolescents. Prevalence, impact, and medication overuse. Neurology66, 193–197 (2006).
   PubMed Web of Science ®Google Scholar
• Schwarz A, Farber U, Glaeske G. Daten zu Analgetikakonsum und Analgetikanephropathie in der Bundesrepublik. Offentl. Gesundheitswes.47, 298 (1985).
   PubMedGoogle Scholar
• Gutzwiller F, Zemp E. Der Analgetikakonsum in der Bevölkerung und sozioökonomische Aspekte des Analgetikaabusus. In: Das Analgetikasyndrom. Mihatsch MJ (Ed). Thieme, Stuttgart, Germany 197 (1986).
   Google Scholar
• Eggen AE. The Tromsø study-frequency and predicting factors of analgesic drug use in a free living population (12–56 years). J. Clin. Epidemiol46, 1297–1304 (1993).
   PubMed Web of Science ®Google Scholar
• Hering-Hanit R, Cohen A, Horev Z. Successful withdrawal from analgesic abuse in a group of youngsters with chronic daily headache. J. Child Neurol.16, 448–449 (2001).
   PubMed Web of Science ®Google Scholar
• Symon DN. Twelve cases of analgesic headache. Arch. Dis. Child.78, 555–556 (1998).
   PubMed Web of Science ®Google Scholar
• Robinson RG. Pain relief for headaches. Cam. Fam. Physician.39, 867 (1993).
   PubMed Web of Science ®Google Scholar
• Granella F, Farina S, Malferrari G, Manzoni GC. Drug abuse in chronic headache – a clinico-epidemiologic study. Cephalalgia7, 15–19 (1987).
   PubMed Web of Science ®Google Scholar
• Micieli G, Manzoni GC, Granella F, Martignoni E, Malferrari G, Nappi G. Clinical and epidemiological observations on drug abuse in headache patients. In: Drug-induced Headache. Diener HC, Wilkinson M (Eds). Springer, NY, USA 20–28 (1988).
   Google Scholar
• Celentano DD, Stewart WF, Lipton RB et al. Medication use and disability among migraineurs – a national probability sample. Headache32, 223–228 (1992).
   PubMed Web of Science ®Google Scholar
• Rapoport A, Weeks R, Sheftell F. Analgesic rebound headache – theoretical and practical implications. In: Proceedings Second International Headache Congress. Olesen J, Tfelt-Hansen P, Jensen K (Eds). Copenhagen, Denmark 448–449 (1985).
   Google Scholar
• Baumgartner C, Wessely P, Bingol C, Maly J, Holzner F. Long-term prognosis of analgesic withdrawal in patients with drug-induced headaches. Headache29, 510–514 (1989).
   PubMed Web of Science ®Google Scholar
• Mathew NT, Kurman R, Perez F. Drug induced refractory headache – clinical features and management. Headache30, 634–638 (1990).
   PubMed Web of Science ®Google Scholar
• Catarci T, Fiacco F, Argentino C, Sette G, Cerbo R. Ergotamine-induced headache can be sustained by sumatriptan daily intake. Cephalalgia14, 374–375 (1994).
   PubMed Web of Science ®Google Scholar
• Kaube H, May A, Diener HC, Pfaffenrath V. Sumatriptan misuse in daily chronic headache. Br. Med. J.308, 1573–1574 (1994).
   PubMed Web of Science ®Google Scholar
• Williams D, Cahill T, Dowson A et al. Usage of triptans among migraine patients – an audit in nine GP practices. Curr. Med. Res. Opin.18, 1–9 (2002).
   PubMed Web of Science ®Google Scholar
• Gaist D, Andersen M, Aarup AL et al. Use of sumatriptan in Denmark in 1994–5-an epidemiological analysis of nationwide prescription data. Br. J. Clin. Pharmacol.43, 429–433 (1997).
   PubMed Web of Science ®Google Scholar
• Gaist D, Tsiropoulus I, Sindrup SH et al. Inappropriate use of sumatriptan-population based register and interview study. Br. Med. J.316, 1352–1353 (1998).
   PubMed Web of Science ®Google Scholar
• Gaist D, Hallas J, Sindrup SH, Gram LF. Is overuse of sumatriptan a problem? A population-based study. Eur. J. Clin. Pharmacol.50, 161–165 (1996).
   PubMed Web of Science ®Google Scholar
• Lucas C, Auray JP, Gaudin AF et al. Use and misuse of triptans in France – data from the GRIM2000 population survey. Cephalalgia24, 197–205 (2004).
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Muessig M, Dzagniza A, Fritsche G, Diener HC, Limmroth V. Rate and predictors for relapses in medication overuse headache – a four year prospective study. Cephalalgia25, 12–15 (2005).
   PubMed Web of Science ®Google Scholar
• Hagen K, Vatten L, Stovner LJ et al. Low socio-economic status is associated with increased risk of frequent headache – a prospective study of 22,718 adults in Norway. Cephalalgia22, 672–679 (2002).
   PubMed Web of Science ®Google Scholar
• Zeeberg P, Olesen J, Jensen R. Efficacy of multidisciplinary treatment in a tertiary referral headache centre. Cephalalgia25, 1159–1167 (2005).
   PubMed Web of Science ®Google Scholar
• Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients – recovery of therapeutic responsiveness. Cephalalgia26, 1192–1198 (2006).
   PubMed Web of Science ®Google Scholar
• Relja G, Granato A, Bratina A, Antonello RM, Zorzon M. Outcome of medication overuse headache after abrupt in-patient withdrawal. Cephalalgia26, 589–595 (2006).
   PubMedGoogle Scholar
• Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G. Advice alone vs. structured detoxification programmes for medication overuse headache – a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia26, 1097–1105 (2006).
   PubMed Web of Science ®Google Scholar
• Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia20, 107–113 (2000).
   PubMed Web of Science ®Google Scholar
• Smith TR. Low-dose tizanidine with nonsteroidal anti-inflammatory drugs for detoxification from analgesic rebound headache. Headache42, 175–177 (2002).
   PubMed Web of Science ®Google Scholar
• Diener H-C, Haab J, Peters C et al. Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced headache. Headache31, 205–209 (1990).
   Web of Science ®Google Scholar
• Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache. An open label study. Headache31, 71–74 (1991).
   PubMed Web of Science ®Google Scholar
• Mei D, Ferraro D, Zelano G et al. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin. Neuropharmacol.29, 269–275 (2006).
   PubMed Web of Science ®Google Scholar
• Haag G, Barr H, Grotemeyer KH, Pfaffenrath V, Ribbat MJ, Diener HC. Prophylaxis and treatment of drug-induced persistent headache. Therapy recommendation of the German Society for Migraine and Headache. Schmerz13(1), 52–57 (1999).
   PubMed Web of Science ®Google Scholar
• Warner JS. The outcome of treating patients with suspected rebound headache. Headache41, 685–692 (2001).
   PubMed Web of Science ®Google Scholar
• Hering R, Steiner TJ. Abrupt outpatient withdrawal of medication in analgesic-abusing migraineurs. Lancet337, 1442–1443 (1991).
   PubMed Web of Science ®Google Scholar
• Haag G, Baar H, Grotemeyer KH et al. Prophylaxe und Therapie des Medikamenteninduzierten Dauerkopfschmerzes. Schmerz13, 52–57 (1999).
   PubMed Web of Science ®Google Scholar
• Katsarava Z, Limmroth V, Finke M et al. Rate and predictors for relapses in medication overuse headache – a one year prospective study. Neurology60, 1682–1684 (2003).
   PubMed Web of Science ®Google Scholar
• Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD; BOTOX CDH Study Group. Botulinum toxin type A for the prophylaxis of chronic daily headache-subgroup analysis of patients not receiving other prophylactic medications – a randomized double-blind, placebo-controlled study. Headache45, 315–324 (2005).
   PubMed Web of Science ®Google Scholar
• Schulte-Mattler WJ, Krack P. BoNTTH Study Group. Treatment of chronic tension-type headache with botulinum toxin A – a randomized, double-blind, placebo-controlled multicenter study. Pain109, 110–114 (2004).
   PubMed Web of Science ®Google Scholar
• Diener HC, Dichgans J, Scholz E, Geiselhart S, Gerber WD, Bille A. Analgesic-induced chronic headache – long-term results of withdrawal therapy. J. Neurol.236, 9–14 (1989).
   PubMed Web of Science ®Google Scholar
• Schnider P, Aull S, Baumgartner C et al. Long-term outcome of patients with headache and drufg abuse after inpatient withdrawal – five year follow-up. Cephalalgia16, 481–485 (1996).
   PubMed Web of Science ®Google Scholar
• Grazzi L, Andrasik F, D’Amico D et al. Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse – outcome at 3 years. Headache42, 483–490 (2002).
   PubMed Web of Science ®Google Scholar
• Evers S, Suhr B, Bauer B, Grotemeyer KH, Husstedt IW. A retrospective long-term analysis of the epidemiology and features of drug-induced headache. J. Neurol.246, 802–809 (1999).
   PubMed Web of Science ®Google Scholar
• Pini LA, Cicero AF, Sandrini M. Long-term follow-up of patients treated for chronic headache with analgesic overuse. Cephalalgia21, 878–883 (2001).
   PubMed Web of Science ®Google Scholar
• Tribl GG, Schnider P, Wober C et al. Are there predictive factors for long-term outcome after withdrawal in drug-induced chronic daily headache? Cephalalgia21, 691–696 (2001).
   PubMed Web of Science ®Google Scholar
• Fritsche G, Eberl A, Katsarava Z, Limmroth V, Diener HC. Drug-induced headache – long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur. Neurol.45, 229–235 (2001).
   Google Scholar
• Silberstein SD, Lipton RB, Dodick DW et al. Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine – a randomized, double-blind, placebo-controlled trial. Headache47, 170–180 (2007).
   PubMed Web of Science ®Google Scholar
• Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia23, 820–824 (2003).
   PubMed Web of Science ®Google Scholar
• Bartolini M, Silvestrini M, Taffi R et al. Efficacy of topiramate and valproate in chronic migraine. Clin. Neuropharmacol.28, 277–279 (2005).
   PubMed Web of Science ®Google Scholar